Schizophrenia is a brain disorder in which chemical signaling, brain structure, and immune function all go wrong in ways that distort a person’s perception of reality, flatten their emotions, and impair their thinking. It affects roughly 0.7% to 1% of the global population, typically appearing in the late teens to mid-twenties, with onset in men averaging 3 to 4 years earlier than in women. What makes schizophrenia so complex is that no single broken mechanism explains it. Instead, several overlapping problems in the brain reinforce each other.
The Dopamine Imbalance
The most established explanation centers on dopamine, a chemical messenger involved in motivation, reward, and how the brain assigns importance to experiences. In schizophrenia, dopamine doesn’t simply run too high or too low. It does both, in different brain circuits, at the same time.
In the brain’s reward and emotion circuits (connecting the midbrain to deeper limbic structures), dopamine activity runs abnormally high. This excess is what drives the hallmark “positive” symptoms: hallucinations, delusions, and paranoia. Essentially, the brain floods everyday perceptions with a false sense of significance. A stranger’s glance feels loaded with meaning. Background noise becomes a voice with a message. The brain’s salience filter is broken, tagging random stimuli as critically important.
Meanwhile, in the prefrontal cortex, the region responsible for planning, decision-making, and working memory, dopamine levels are too low. This shortfall produces the “negative” and cognitive symptoms: difficulty concentrating, emotional flatness, loss of motivation, and trouble organizing thoughts. Recent research shows these two imbalances aren’t independent. Elevated dopamine signaling in one area can actively suppress dopamine release in the prefrontal cortex, meaning the positive symptoms and cognitive problems may worsen each other. Excessive, misfiring dopamine may also mask the brain’s normal reward signals, making it harder to learn from positive experiences and contributing to the withdrawal and apathy that many people with schizophrenia experience.
Beyond Dopamine: The Glutamate Problem
Dopamine isn’t the whole story. A second major chemical system, glutamate, the brain’s primary excitatory signal, also malfunctions. Specifically, a type of glutamate receptor called the NMDA receptor doesn’t work properly in schizophrenia. Researchers first noticed this because drugs that block NMDA receptors (like ketamine and PCP) produce symptoms strikingly similar to all three symptom categories of schizophrenia: psychosis, emotional blunting, and cognitive difficulty.
The dysfunction appears to hit one cell type especially hard: fast-spiking inhibitory neurons that normally act as the brain’s brakes. When NMDA receptors on these “braking” neurons don’t function correctly, they can’t do their job. The result is that excitatory neurons fire without proper regulation, creating a kind of neural chaos. This disinhibition cascades downstream, disrupting dopamine signaling and interfering with the synchronized brain-wave patterns needed for working memory and attention. Oxidative stress, a form of cellular damage from reactive molecules, appears to worsen NMDA receptor problems in these same inhibitory neurons, creating a self-reinforcing cycle.
The Brain’s Immune Cells Turn Destructive
The brain has its own immune cells called microglia. In a healthy brain, microglia prune unnecessary connections between neurons during development, clear debris, and fight infection. In schizophrenia, these cells appear to become overactivated, shifting into a pro-inflammatory state and releasing harmful signaling molecules.
People with schizophrenia show elevated levels of inflammatory markers both in their blood and in cerebrospinal fluid. Patients with recent-onset schizophrenia show significantly increased levels of one inflammatory signal, IL-6, in both plasma and spinal fluid. Post-mortem brain tissue from people with schizophrenia reveals activation of a specific inflammatory pathway called the inflammasome, with increased production of inflammatory molecules and signs of cellular stress.
The most consequential effect may be excessive synaptic pruning. Synapse loss is one of the central features of schizophrenia, and overactivated microglia appear to strip away too many connections, particularly on glutamate-using neurons. This provides a direct link between the immune dysfunction and the glutamate signaling problems described above. In other words, the brain’s own maintenance crew is tearing out wiring it shouldn’t be.
Physical Changes in Brain Structure
These chemical and immune disruptions leave visible marks. Brain imaging studies consistently show that people with schizophrenia have enlarged fluid-filled spaces (ventricles) inside the brain and reduced gray matter, the tissue that contains neuron cell bodies. The volume differences are modest in absolute terms, around 2% less total gray matter and roughly 7% less in frontal and temporal regions, but they are statistically reliable across large studies. The affected areas include the frontal lobes (planning, impulse control), the temporal lobes (language processing, auditory perception), and the hippocampus (memory formation).
These structural differences aren’t static. People with schizophrenia lose gray matter at a faster rate over time than healthy individuals, roughly an additional 0.5% per year. This progressive loss helps explain why cognitive symptoms can worsen over the course of the illness, even when psychotic episodes are controlled.
Genetics Set the Stage
Schizophrenia is strongly heritable. A nationwide Danish twin study estimated heritability at 79%, meaning that the vast majority of variation in who develops the disorder is explained by genetic differences. Among identical twins, if one has schizophrenia, the other develops it about 33% of the time. For fraternal twins, that drops to 7%.
That 33% concordance rate in identical twins is telling. If schizophrenia were purely genetic, identical twins would always share the diagnosis. The gap means environmental factors play a significant role in whether a genetic predisposition actually becomes the disorder. Prenatal infections, childhood adversity, cannabis use during adolescence, and urban upbringing have all been linked to increased risk in genetically vulnerable individuals. No single gene causes schizophrenia. Instead, hundreds of common genetic variants each contribute a small amount of risk, affecting pathways involved in dopamine signaling, glutamate receptors, immune function, and synaptic pruning, the very mechanisms that go wrong in the disorder.
The Prodromal Phase: What Happens Before Psychosis
Schizophrenia rarely appears overnight. Most people go through a prodromal phase, a period of gradual changes that precede the first full psychotic episode. Nonspecific symptoms like anxiety, depression, sleep disturbances, and mood swings often appear first, sometimes years before diagnosis. Closer to the onset, roughly within the year before a psychotic break, more specific warning signs emerge: unusual perceptual experiences (sounds seeming louder or distorted, brief visual anomalies), odd beliefs or magical thinking, and difficulty with attention and memory.
Observable behavioral changes during this phase include marked social withdrawal, declining performance at school or work, neglect of personal hygiene, vague or tangential speech, flattened emotions, and a notable loss of initiative or energy. These changes are easy to dismiss as depression, adolescent moodiness, or substance use, which is one reason the average gap between symptom onset and treatment remains long.
How Diagnosis Works
There is no blood test or brain scan that diagnoses schizophrenia. Diagnosis is clinical, based on observed symptoms and their duration. The DSM-5 requires at least two of the following symptoms present for a significant portion of a one-month period: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, or negative symptoms like emotional flatness and lack of motivation. At least one of those two must be delusions, hallucinations, or disorganized speech. Continuous signs of the disturbance must persist for at least six months total, including that one-month active phase. If all the criteria are met but the illness has lasted less than six months, a different diagnosis (schizophreniform disorder) is given instead.
How Treatment Targets the Brain
All current antipsychotic medications work primarily by blocking dopamine receptors in the brain, specifically the D2 receptor. This directly counteracts the excess dopamine signaling in the reward and emotion circuits responsible for hallucinations and delusions. Medications reach their maximum effectiveness at around 80% receptor blockade. This creates a narrow therapeutic window, because once blockade exceeds 75% to 85%, the risk of movement-related side effects like stiffness, tremor, and restlessness rises sharply. At 90% blockade, the odds of these side effects nearly triple compared to lower doses.
This mechanism explains both the strengths and limitations of current treatment. Antipsychotics are reasonably effective at reducing positive symptoms because they directly address dopamine excess. But they do little for negative and cognitive symptoms, which stem from dopamine deficits in the prefrontal cortex and from glutamate and immune dysfunction that these medications don’t target.
Long-Term Outlook
Schizophrenia is a chronic condition, but its trajectory varies enormously. A 10-year follow-up study of people after their first psychotic episode found that 50% achieved clinical recovery, defined as maintaining mild or minimal symptoms for at least two years while also holding a job or attending school, living independently, and socializing without professional supervision. That means half of people who experience a first episode can, with sustained treatment, reach a point where the illness no longer dominates daily life. The other half face a more persistent course, with ongoing symptoms or functional limitations that require continued support. Early treatment, consistent medication, and strong social networks are the strongest predictors of which trajectory someone follows.